With policies governing approval and conduct of clinical trials embroiled in judicial and regulatory hurdles, India’s potential for developing new drugs is under threat leading to far-reaching consequences for patients.
On account of the limbo in approval of clinical trials, the industry estimates a loss of around $150-200 million this year alone.
The Supreme Court will hear the matter on Monday, which will decide the future of 162 clinical trials — related to new drugs (including new chemical entities) and new fixed dose combinations — approved by the health ministry.
The government will try to assure the apex court that all possible precautions were taken when approving these trials.
The health ministry is betting on the Ranjit Roy Choudhury committee report, which includes proposals on high compensation for clinical trial patients, setting up of review committees and timeline for approval of trials to thwart any possible shutdown of the clinical trial industry by the apex court.
Earlier, the Supreme Court had expressed concerns about drug trials being permitted on humans without comprehensive rules to regulate the approval process.
According to health ministry sources, all the 162 trials were approved in accordance with the Choudhury committee proposals.
The government has, however, not granted a formal approval to those proposals.
The uncertainty is also delaying development of novel moleclues by pharma companies like Biocon which is awaiting regulatory clearance to conduct development trials on its new oral insulin drug, which the company believes will transform treatment for diabetes.
According to an executive from a top pharma firm, which also conducts clinical trials in India, any freeze could see more business moving to locations like Malaysia and Singapore.
Drug trials, which is the most critical process in new drug development, take around 5-6 years and account for a major chunk of the drug discovery spend of pharmaceutical MNCs.
The domestic clinical research organisation market fell from $485 million in 2011 when some 320 clinical trials were approved to $300 million last year when around 250 trials were given the government nod.
Contract research organisations (CROs) contend that the regulatory environment in India is leading to